Merck Patent Gmbh

Vertex Pharmaceuticals, Inc.

Northeastern University

Shashank Kulkarni

Alexandros Makriyannis

Spyridon P Nikas

David J Lauffer

Guy W Bemis

Tiansheng Wang

Pan Li

Qing Tang

Steven M Ronkin

Hongbo Deng

Richard Dana Caldwell

Nathan D Waal

Michael John Boyd

Hui Qiu

Reinaldo Jones

Michael P Clark

Constantin Neagu

Justin Potnick

Philip N Collier

Ganeshsingh Arjunsingh Thakur

Warren A Dorsch

Mac Arthur Johnson, Jr

Marina S Penney

Darin Takemoto

Russell R Hoover

Huijun Dong

Kishan Chandupatla

Rishi Sharma

Lipin Ji

Christos Iliopoulos Tsoutsouvas

Henry Yu

Lesley Liu-bujalski

Philip Collier

Mac Arthur Johnson

The present invention relates to fused imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.

Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK)

The present invention provides compounds of Formula I', or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

Antiproliferation compounds and uses thereof

Disclosed are compounds and compositions that modulate cannabinoid receptors, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors. This disclosure is directed to methods of treating cannabinoid dependence, neuropathy, inflammation, glaucoma, a neurodegenerative disorder, a motor function disorder, a gastrointestinal disorder, hypothermia, emesis, loss of appetite, or anorexia associated with AIDS.

Cannabinergic compounds and uses thereof

Novel cannabinoid ligands represented by the general formulas I, II, and III and methods for preparation and use within which one or more of a fluorescent ligand, nitroxide spin label, metal chelate, biotin moiety, or group with enhanced polarity may be incorporated. The compounds can bind to and modulate the cannabinoid CB1 and CB2 receptors and thereby considered specific ligands for these receptors. Some of the disclosed compounds that bind to cannabinoid CB1 and CB2 receptors can exhibit tight or irreversible binding characteristics for these receptors. Due to the presence of the imaging/diagnostic and/or therapeutic functional groups including fluorescent groups, nitroxide spin labels, metal chelates, biotin moieties, and groups with enhanced polarity, the disclosed compounds may be useful as imaging/diagnostic tools and/or therapeutic agents.

Labelled cannabinergic ligands and related analogs

Growing community of inventors

Billerica, MA, United States of America

Shashank Kulkarni